US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Biosergen Completes Enrollment of First Cohort in BSG005 Proof-of-Concept Trial

October 7, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseases, today announced the successful enrollment of the first five-patient cohort in its proof-of-concept clinical trial. The trial is evaluating the company’s drug candidate, BSG005, as a rescue therapy for patients who have failed previous standard-of-care antifungal treatments due to either lack of efficacy or safety or patients with mild to moderate kidney impairment.“We are thrilled to have filled the first cohort,” said Tine Olesen, CEO of Biosergen.

BioStock: Biosergen’s CEO: “The first patient regained his health”

In Biosergen’s Q2 report, the company  highlights the successful start of the phase Ib study with BSG005. The first patient with invasive fungal disease recovered and preserved both his lungs by avoiding surgery after being treated with BSG005, something the company describes as “very remarkable.” BioStock reached out to CEO Tine Olesen to learn more about this success and the company’s financial status.Read the interview with Tine Olesen at biostock.se:https://www.biostock.se/en/2024/09/biosergens-ceo-the-first-patient-regained-his-health/This is a press release from BioStock -

Biosergen publishes interim report for second quarter 2024

Friday, August 30, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the second quarter 2024. The interim report is available as an attached document and on the company website (www.biosergen.net)Biosergen have treated the first patient with BSG005 ” We got the final permission to start our first patient study in Q2 and shortly after we recruited the first patient. The patient was diagnosed with Mucormycosis (black fungus) which is one of the most difficult  invasive fungal infections to treat. The patient was treated for 28 days and recovered with

Biosergen have completed treatment of the first patient with BSG005

Friday, August 30, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby announce the completion of treatment of the first patient with BSG005Invasive fungal infections represent a serious health threat, claiming 2.5 mill lives annually. There is growing resistance toward current therapy and the lack of broad-spectrum safe therapies has the WHO on high alert. It needs attention, and we need novel effective safe treatments. Biosergen is developing BSG005 designed to be safe, efficacious and broad-spectrum. We have been focusing on the starting our first patient trial in India. As

BioStock: Biosergen on dosing the first patient with life-threatening fungal disease

The first patient has been dosed in Biosergen’s clinical phase Ib trial with BSG005, intended as rescue therapy for invasive fungal infection to increase survival rates for these critically ill patients. Topline results are anticipated by year-end or early 2025. BioStock reached out to CEO Tine Kold Olesen to learn more about the latest achievement.Read the interview at biostock.se:https://www.biostock.se/en/2024/07/biosergen-on-dosing-the-first-patient-with-life-threatening-fungal-disease/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

First Patient in Biosergen Clinical Trial Treating with BSG005 for Life Threatening Fungal Infection

Stockholm, Sweden – July 12, 2024 – Biosergen AB (“Biosergen”) is pleased to announce that the first patient suffering from an invasive fungal infection has been dosed with BSG005 as rescue therapy.‘Today marks a significant milestone as the first patient has received the first dose of our lead candidate BSG005. The goal with the study is to increase survival rates for these very ill patients with difficult to treat fungal strains or/and with resistance to current antifungal treatment. There is a significant unmet medical need for the many millions of people infected with and dying from

Bulletin from the annual general meeting on June 14, 2024 in Biosergen AB

Today, on June 14, 2024, the annual general meeting was held in Biosergen AB. A summary of the adopted resolutions follows below. All resolutions were adopted in accordance with the presented proposals, which are described in detail in the notice to the annual general meeting available on the Company’s website, www.biosergen.net.Resolution on adoption of accounts and allocation of the Company’s profits The annual general meeting resolved to adopt the profit and loss statement and balance sheet as well as the consolidated profit and loss statement and consolidated balance sheet. The

Biosergen to welcome two new board members based on election at the Annual General Meeting

Stockholm, Sweden – June 11, 2024 – Based on the change in ownership during successful capital raise earlier this year major shareholders in Biosergen AB (Biosergen) present a proposal for the election of the board of directors ahead of the annual general meeting 2024Ahead of the annual general meeting in Biosergen to be held on Friday, June 14, 2024, major shareholders propose changes to the current board composition. Major shareholders propose that  new member Anna Ljung is elected as chairperson of the board for the period until the end of the annual general meeting in 2025 and that

Biosergen receives the final permission required to test lead candidate BSG005 in patients with invasive fungal infection.

Stockholm, Sweden – June 11, 2024 – Biosergen AB (“Biosergen”) is pleased to announce that it has received permission to test BSG005 as rescue therapy in patients with invasive fungal infections.Biosergen’s partner, Alkem Laboratories Limited (“Alkem”), has received an approval of the Clinical Trial Application and an import license from the Central Drugs Standard Control Organization (CDSCO) in India. The approval and import license allow for the initiation of the first patient trial for BSG005. A clinical trial designed to address unmet medical needs in invasive fungal infections.

BioStock: Biosergen towards first-in-patient trial with antifungal therapy

During Q1, Biosergen took major steps towards its goal to address the hidden threat of fungal infections. Not only was the company able to secure the necessary funding for the upcoming clinical phase Ib trial with BSG005, it also received the approval from the local authorities in India to procceed with the study. BioStock reached out to CEO Tine Kold Olesen for a comment on the company’s progress.Read the article at biostock.se: Biosergen towards first-in-patient trial with antifungal therapy - BioStock 

Biosergen publishes interim report for first quarter 2024

Friday, May 31, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the first quarter 2024. The interim report is available as an attached document and on the company website (www.biosergen.net)Summary of the Interim Report for Q1 2024 2024 2023 2023TSEK Jan-Mar Jan-Mar Jan-Dec Profit/loss Other income 693 5.315 9.378Profit/loss before depreciation (EBITDA -6.798 -5.029 -27.265Operating

Notice of annual general meeting in Biosergen AB

The shareholders of Biosergen AB, Reg. No. 559304-1295, (the “Company”) are invited to attend the annual general meeting to be held on Friday June 14, 2024, at Fogdevreten 2A, SE-171 65 Solna, at 11:00.Right to participate and notice of participationShareholders wishing to participate in the annual general meeting must: · partly be listed in the Company’s share register kept by Euroclear Sweden AB as of Wednesday June 5 2024; and · partly have given a notice of their intent to participate to the Company no later than on Monday June 10 2024 by post to Advokatfirman Hammarskiöld &

BioStock: Biosergen's CEO - "this is a global health threat and it needs attention"

The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation have announced a USD 300 million initiative to support solutions for major global health threats, including infectious diseases. BioStock spoke with Tine Kold Olesen, CEO at Biosergen, a Swedish biotech developing drugs targeting life-threatening fungal infections, to get her take on this partnership and how it might impact small drug developers like Biosergen.Read the article at biostock.se: Biosergen's CEO: "this is a global health threat and it needs attention" - BioStock 

Conversion of paid subscribed units and first day of trading with warrants of series TO3

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED KINGDOM, THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, HONG KONG, NEW ZEALAND, SINGAPORE, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. The rights issue of shares and warrants of series TO3 in Biosergen AB (“Biosergen” or the “Company”), which was announced on January 30, 2024 and approved by the extraordinary general meeting on March 1, 2024 (the “Rights Issue”), has been registered with the

Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED KINGDOM, THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, HONG KONG, NEW ZEALAND, SINGAPORE, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Biosergen AB (“Biosergen” or the “Company”) has, as previously announced on March 26, 2024, completed the rights issue of units, consisting of shares and warrants of series TO3 which was announced on January 30,

Biosergen announces the outcome in the rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED KINGDOM, THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, HONG KONG, NEW ZEALAND, SINGAPORE, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Biosergen AB (“Biosergen” or the “Company”) has completed the rights issue of units, consisting of shares and warrants of series TO3, which was announced on January 30, 2024 (the “Rights Issue”), with the

BioStock Investor Pitch: Biosergen

In the BioStock Studio, Swedish Biosergen talks about the company’s vision, market plan and strategy to take its product through the first patient study and on towards a global market. Strengthened by its recent agreement with Alkem, the company intends to advance its antifungal drug candidate BSG005 further by an ongoing rights issue of SEK 40.5 million.Watch Biosergens CEO Tine Kold Olesen present the company in the BioStock Investor Pitch: BioStock Investor Pitch – Biosergen This is a press release from BioStock -

Members of the board of directors and management subscribe in ongoing rights issue

Biosergen AB (publ) (“Biosergen” or the “Company”) announce that members of the board of directors, through affiliated companies, management team and employees subscribe for 6,563,092 units, corresponding to SEK 15.8 million in the ongoing rights issue of units (the “Rights Issue”).Subscriptions from the board of directors and management teamThe largest shareholder Östersjöstiftelsen, represented by board member Mattias Klintemar, subscribes for 5,625,000 units, corresponding to SEK 13.5 million in accordance with previously communicated subscription commitment. In addition, the second

BioStock: Rights issue to give Biosergen first in-human efficacy data

Recently having closed a partnership deal with Alkem, Biosergen is advancing its antifungal drug candidate BSG005 through clinical studies. With Alkem later financing phase II and III studies, Biosergen is now carrying out a SEK 40.5 million rights issue to fund a first-in-patient safety and efficacy study in a patient group with no other treatment option.Read the full article at biostock.se : https://www.biostock.se/en/2024/03/rights-issue-to-give-biosergen-first-in-human-efficacy-data/ This is a press release from BioStock - Connecting Innovation &

BioStock: Biosergen attacks invisible threat of fungal infections

How big is the threat of fungal infections and the strains that develop drug resistance? Swedish biotech company Biosergen develops antimyotic drugs that they hope will become market leading. Newly appointed CEO Tine Kold Olesen visited the BioStock Studio to discuss the invisible threat of fungi and the company’s partnership for the Indian market. In addition, CFO Niels Laursen talked about the ongoing rights issue of SEK 40.5 million and what it will finance.Watch the full interview at biostock.se : https://www.biostock.se/en/2024/03/biosergen-attacks-

Biosergen CEO to BioStock: “Positive data give us a strong value proposition”

Biosergen is carrying out a SEK 40.5 million rights issue to conduct a first-in-patient safety and efficacy study with the antifungal drug candidate BSG005. This will set the stage for the phase II and III clinical studies, which will be financed and undertaken in collaboration with the Indian partner, Alkem. BioStock contacted Biosergen CEO Tine Kold Olesen to get more insights.Read the full article at biostock.se : https://www.biostock.se/en/2024/03/biosergen-ceo-positive-data-give-us-a-strong-value-proposition/ This is a press release from BioStock -

Biosergen publishes prospectus due to rights issue of units

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, HONG KONG, NEW ZEALAND, SINGAPORE, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Biosergen AB (publ) (“Biosergen” or the “Company”) has prepared an EU growth prospectus (the “Prospectus”) for the forthcoming issue of units consisting of shares and warrants with preferential rights for existing shareholders (

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe